Canaccord Genuity Raises PT of Regeneron Pharmaceuticals (REGN) to $525 from $460
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Regeneron (REGN) PT Lifted to $507 at Brean Capital Amid Strong Eylea Sales
May 8, 2015 8:26 AM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Regeneron Pharma (NASDAQ: REGN) to $507.00 (from $450.00) following strong Q1 US Eylea sales.
Aschoff commented, "1Q15 US Eylea sales of $541 million beat consensus of $537 million. Sales growth comprised a 10% QoQ increase in underlying physician demand, offset by a modest QoQ decrease in inventory levels. Importantly, Regeneron raised its guidance for 2015 US Eylea sales... More
Regeneron Pharma (REGN) Estimates, PT Lifted at Piper Jaffray
May 8, 2015 7:39 AM EDTPiper Jaffray analyst Edward Tenthoff raised his price target on Regeneron Pharma (NASDAQ: REGN) to $484.00 (from $415.00) following results but reiterated a Neutral rating.
Tenthoff commented, "U.S. EYLEA sales of $541 million in 1Q:15 topped our $534 million estimate and management increased 2015 sales growth... More
Regeneron Pharma (REGN) PT Lifted to $490 at Roth Capital
May 7, 2015 1:21 PM EDTRoth Capital analyst Joseph Pantginis raised his price target on Regeneron Pharma (NASDAQ: REGN) to $490.00 (from $461.00) following Q1 results while retaining a Neutral rating.
Pantginis commented, "Regeneron announced 1Q15 results posting GAAP EPS of $0.66 (non-GAAP of $2.88) compared with our estimate of $0.97. 1Q15... More
Regeneron (REGN) Tops Q1 EPS by 20c; Boosts U.S. EYLEA Sales Outlook
May 7, 2015 6:34 AM EDTRegeneron (NASDAQ: REGN) reported Q1 EPS of $2.88, $0.20 better than the analyst estimate of $2.68. Revenue for the quarter came in at $870 million versus the consensus estimate of $820.3 million.
Net product sales were $545 million in the first quarter of 2015, compared to $362 million in the... More
